Aquestive Therapeutics (AQST) H.C. Wainwright 26th Annual Global Investment Conference summary

Conference overview

• H.C. Wainwright's 26th Annual Global Investment Conference featured presentations, panels, and one-on-one meetings, with sessions available both live and streaming from September 9–11, 2024.

• Aquestive Therapeutics presented, focusing on their orally soluble drug delivery technologies and pipeline.

Company highlights and pipeline

• Utilizes PharmFilm and epinephrine prodrug technologies to improve drug delivery and patient outcomes.

• Achieved $50 million in revenue last year, with six FDA approvals and products available on six continents.

• Pipeline includes Anaphilm (epinephrine sublingual film), Libervant (diazepam buccal film), and AQST-108 topical gel.

• Libervant is being launched for ages 2–5, with plans to expand to all age groups by 2027 and projected annual sales of $100 million or more.

• Anaphilm and AQST-108 are seen as major growth drivers, with a combined potential to reach $1.5 billion in revenue over the next 5–7 years.

Market opportunity and unmet needs

• Anaphylaxis affects 33 million Americans with food allergies, but fewer than 5 million epinephrine prescriptions are written annually.

• The current epinephrine market is valued at $1 billion, with potential to double as new products enter.

• Recent FDA approval of a nasal spray (Neffy) expands options, but no oral products exist yet.

• Low carry rates for current medical devices are attributed to inconvenience and behavioral factors.